Exclusive Summary

• • Global LOE completed (US/EU/JP ~2014–2016) and ODT-specific protection expired, enabling fast entry and broad tender eligibility.
• • Targets large, chronic populations (schizophrenia ~24M, bipolar ~40M; adjunctive MDD as a defined niche), ensuring steady demand.
• • ODT improves convenience and reduces cheeking/spitting, differentiating vs plain tablets for dysphagia and low-adherence patients.
• • ODT competition is moderate versus crowded plain tablets; white-space remains in LATAM/MENA/SEA for distributor-led expansion.
• • With ICH-compliant CTD+BE and Zone IVb stability, pricing can be 90%+ below originator and only a 10–30% premium vs plain tablets, boosting tender win rates.